How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market
- By Product Type: Blood Glucose Test Strips, Lancets, Blood Glucose Meters
- By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Laboratories
- By Technology: Electrochemical Sensors, Optical Sensors, Enzymatic Sensors
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales
- By Application: Self-Monitoring of Blood Glucose (SMBG), Professional Use in Clinical Settings, Research and Development
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Blood Glucose Test Strips leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 3
End User 4
Technology 3
Distribution Channel 4
Application 3
Companies profiled
Roche Diabetes Care
Abbott Laboratories
Ascensia Diabetes Care
LifeScan (a Johnson & Johnson company)
Medtronic
Bayer AG
Nipro Corporation
Arkray Inc.
Tosoh Corporation
Sinocare Inc.
A. Menarini Diagnostics
Trividia Health
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Ascensia Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →LifeScan (a Johnson & Johnson company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Arkray Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Tosoh Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sinocare Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →A. Menarini Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Trividia Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →i-SENS Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Terumo Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Beijing Choice Electronic Technology Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$5,449M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Blood Glucose Test Strips67.8
- Lancets22.5
- Blood Glucose Meters9.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$758.5M → $1,875M · 12.0%
Europe$528.6M → $1,168M · 10.4%
Asia Pacific$482.7M → $1,021M · 9.8%
Latin America$298.8M → $695.6M · 11.1%
Middle East and Africa$229.8M → $558.9M · 11.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.352026
11.362027
11.372028
11.382029
11.402030
11.412031
11.422032
11.442033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diabetes Care14.3
- Abbott Laboratories17.6
- Ascensia Diabetes Care9.8
- LifeScan (a Johnson & Johnson company)7.9
- Medtronic11.1
- Bayer AG11.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type24.8%
End User17.2%
Technology9.4%
Distribution Channel24.3%
Application24.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.2
- Europe22.0
- Asia Pacific19.2
- Latin America13.1
- Middle East and Africa10.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diabetes Care | 92 | 99 | 81 | 99 | 82 | 89 | 90 |
| Abbott Laboratories | 73 | 81 | 90 | 75 | 73 | 70 | 77 |
| Ascensia Diabetes Care | 67 | 63 | 70 | 81 | 65 | 80 | 71 |
| LifeScan (a Johnson & Johnson company) | 82 | 64 | 70 | 82 | 63 | 61 | 70 |
| Medtronic | 66 | 54 | 61 | 61 | 70 | 61 | 62 |
| Bayer AG | 49 | 57 | 50 | 48 | 68 | 50 | 54 |
| Nipro Corporation | 49 | 56 | 42 | 41 | 46 | 58 | 49 |
| Arkray Inc. | 41 | 37 | 49 | 40 | 57 | 53 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diabetes Care
- Abbott Laboratories
- Ascensia Diabetes Care
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diabetes Care | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Abbott Laboratories | ◐ | ◐ | ◐ | ✓ | ◐ | − |
| Ascensia Diabetes Care | − | ◐ | ◐ | ◐ | ◐ | ✓ |
| LifeScan (a Johnson & Johnson company) | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Medtronic | − | − | ◐ | − | − | ✓ |
| Bayer AG | − | ◐ | − | − | ◐ | ◐ |
| Nipro Corporation | ◐ | ◐ | − | − | ◐ | ◐ |
| Arkray Inc. | − | − | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Diabetes Care90
2Abbott Laboratories77
3Ascensia Diabetes Care71
4LifeScan (a Johnson & Johnson company)70
5Medtronic62
6Bayer AG54
7Nipro Corporation49
8Arkray Inc.46
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Roche Diabetes Care
Challenger3
Strong scale, closing on the leaders.
Abbott LaboratoriesAscensia Diabetes CareLifeScan (a Johnson & Johnson company)
Contender1
Focused players with pockets of strength.
Medtronic
Niche3
Specialists in a single segment or region.
Bayer AGNipro CorporationArkray Inc.
Go-to-market strategy
Land Product Type in North America, then scale across Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market — a $336M beachhead inside a $5.80B market.
Beachhead (SOM)$336Mobtainable near-term
Serviceable (SAM)$2.20Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Blood Glucose Test Strips
Best fit — highest urgency & budget in Product Type.
Economic buyer78 fit
Lancets
Strong fit — clear ROI and a fast path to value.
End user67 fit
Blood Glucose Meters
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified20%
Evaluation13%
Closed-won7%
$20.1KCAC
$69KLTV
3.4:1LTV : CAC
< 2 moCAC payback
Investment thesis
Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market is a durable-growth opportunity — $5.44B by 2033, compounding at 6.6%.
TAM · 2025$3.27Btoday
TAM · 2033$5.44Bforecast
CAGR6.6%2027–2033
Cumulative$38.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.44BTotal addressable market
SAM$1.98BServiceable available market
SOM$341MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.6% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.44BLarge & growingTAM by 2033 at 6.6% CAGR
$1.98BServiceable nowreachable with today’s model
$341MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.24BBear4.3% CAGR
$5.44BBase6.6% CAGR
$6.96BBull8.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market — a $9.25B market by 2033. Plan: grow share from 9.0% to 15.4%.
Market size · 2033$9.25Btotal addressable
Market CAGR9.9%2027–2033
Target share15.4%from 9.0% today
Revenue ambition$1.42Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 15.4% | On track |
| Revenue | $912M | $1.42B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.4% | 38.4% | On track |
| Customer retention | 86.7% | 92.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $152M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentBehind
Sales deck · value proposition
Win the Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market conversation — a $8.79B market you can size, segment and defend in minutes.
Market size · 2033$8.79Btotal opportunity
Growth6.2%CAGR to 2033
Addressable buyers1,486+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 3 mopayback period
$71K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Roche Diabetes CareAbbott LaboratoriesAscensia Diabetes CareLifeScan (a Johnson & Johnson company)MedtronicBayer AGNipro CorporationArkray Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Glucose (SMBG) (Test Strips, Lancet, Meter) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Glucose Devices Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportBlood Glucose Meter Accessorie Market
Market size, share, segmentation and regional forecast.
$842M market · 2025 base year
View reportBlood Glucose Meter, Blood Glucose Detection Test Disc (Glucose Oxidase) Market
Market size, share, segmentation and regional forecast.
$788M market · 2025 base year
View reportBlood Glucose Meters - Pipeline Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBlood Glucose Monitor Market
Blood Glucose Monitor Market is valued at USD 7.2 Billion in 2025 and is expected to reach USD …
$7.2B market · 2025 base year
View reportBlood Glucose Monitoring Consumables Market
Market size, share, segmentation and regional forecast.
$965M market · 2025 base year
View reportBlood Glucose Monitoring Device Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBlood Glucose Monitoring System (BGMS) Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBlood Glucose Monitoring Systems Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBlood Glucose Sensor Patch Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBlood Glucose Sensors Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportBlood Glucose Strip Market
Market size, share, segmentation and regional forecast.
$516M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.